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Abstract  30 
Coenzyme Q10 (CoQ10) plays a critical role in mitochondrial oxidative phosphorylation by 31 
serving as an electron carrier in the respiratory electron transport chain. CoQ10 also functions 32 
as a lipid-soluble antioxidant by protecting lipids, proteins and DNA damaged by oxidative 33 
stress. CoQ10 deficiency has been associated with a number of human diseases including 34 
mitochondrial diseases, neurodegenerative disorders, cardiovascular diseases, diabetes, 35 
cancer, and with the ageing process. In many of these conditions CoQ10 supplementation 36 
therapy has been effective in slowing or reversing pathological changes. Oxidative stress is a 37 
major contributory factor in the process of retinal degeneration. In this brief review, we 38 
summarize the functions of CoQ10 and highlight its use in the treatment of age-related 39 
macular degeneration and glaucoma. In light of these data we propose that CoQ10 could have 40 
therapeutic potential for other retinal diseases. 41 
 42 
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1. Introduction  60 
Coenzyme Q10 (CoQ10), first identified by Crane et al, is a 1,4-benzoquinone-containing 61 
molecule with a hydrophobic tail harbouring 10 isoprenyl units (1). CoQ10 is ubiquitously 62 
distributed in various tissues and blood and presents in all cell membranes (2, 3). It is 63 
synthesized in the mitochondrial matrix and at least 12 genes are required for its biosynthesis; 64 
mutations in some of these genes have been reported to cause CoQ10 deficiencies (4). CoQ10 65 
exists in more than one state within the body: oxidized (ubiquinone), partially reduced 66 
(semiquinone radical) and reduced (ubiquinol) forms (Figure 1A); the ratio of oxidized and 67 
reduced forms in various cellular membranes is dependent on the metabolic state of 68 
individual cells. Within the inner mitochondrial membrane, the CoQ10 pool is found in two 69 
main forms: approximately 30% is protein bound and principally participates in oxidative 70 
phosphorylation; the remainder is not protein-bound and contributes to different functions, 71 
the major one being as a lipophilic antioxidant (5). CoQ10 is required for cellular ATP 72 
generation by shuttling electrons from complexes I and II to complex III in the mitochondrial 73 
respiratory chain (Figure 1 B) (6). The oxidized form of CoQ10 is able to undergo two 74 
electron reductions in a reaction involving complex I and complex II, resulting in the 75 
formation of ubiquinol: subsequently, electrons are passed to complex III. Typically, tissues 76 
that are heavily reliant on oxidative metabolism, such as the myocardium, present a high 77 
concentration of CoQ10. It is the only naturally occurring endogenous lipid-soluble 78 
antioxidant which, in its reduced and active form ubiquinol, may act as a direct free radical 79 
scavenger, inhibiting the oxidation of lipids, proteins and DNA (6) or may act synergistically 80 
with other antioxidants, such as vitamin E, regenerating its oxidised form, tocopheryl radical. 81 
CoQ10 also demonstrates a regulatory role in the expression of genes involved in cell 82 
signalling, metabolism and nutrition transport (7). Moreover, it has been shown to exert an 83 
anti-inflammatory effect by reducing LPS-induced secretion of TNF-α, possibly via the 84 
NFkB1-dependent pathway (8). 85 
      CoQ10 deficiency is mainly associated with encephalomyopathy, infantile multisystemic 86 
disease, cerebellar ataxia, pure myopathy, and cardiofaciocutaneous syndrome. The causes of 87 
CoQ10 deficiencies are primarily due to mutations in ubiquinone biosynthesis genes (COQ2, 88 
PDSS1 and 2, and ADCK3) or in genes indirectly related to CoQ10 biosynthesis (APTX, 89 
BRAF, and ETFDH). However, the causes of CoQ10 deficiency still remain unknown in a 90 
large number of patients (4). Lowered levels of CoQ10 have been reported in different 91 
clinical conditions, including cardiovascular disease, diabetes, cancer, and neurodegenerative 92 
disease. More generally, a subliminal deficit of CoQ10 might also be observed in 93 
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paraphysiological states such as ageing: synthesis in human is known to peak around the third 94 
decade of life and subsequently decreases with age. Moreover, the use of commonly 95 
prescribed drugs that interfere with the mevalonate pathway, such as statins, are known also 96 
to impact cellular coenzyme Q10 level. Interestingly, intracellular content of CoQ10 is close 97 
to the Km of the respiratory complexes, implying that even slight variations in the CoQ10 98 
content translate into dramatic changes in the mitochondrial bioenergetics that is known to be 99 
a major site of production of reactive oxygen species. Oral CoQ10 therapy has been applied 100 
to different forms of CoQ10 deficiency, with resulting significant clinical improvements (4). 101 
Oxidative stress plays an important role in the pathogenesis of vascular diseases, diabetes and 102 
neurodegenerative disease. Due to its antioxidant properties, CoQ10 supplementation has 103 
been beneficial in the treatment of the above diseases. Numerous studies have reported that 104 
CoQ10 administration improved cardiovascular function (2,9,10). CoQ10 supplementation in 105 
three separate clinical trials of  dyslipidemic type 2 diabetic patients showed raised plasma 106 
CoQ10 levels, improved endothelial function, and decreased blood pressure and glycosylated 107 
haemoglobin (HbA1C) (11-13). CoQ10 has been used in different neurodegenerative diseases, 108 
including Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease. CoQ10 109 
supplementation seemed to slow progression of Parkinson’s disease (9, 14). 110 
      CoQ10 is detectable in both choroid and retina, though levels are relative low when 111 
compared to other oxygen-demanding tissues (15, 16). Similarly to other tissues, the level of 112 
CoQ10 in the retina declines with age (15). There is increasing evidence that CoQ10 protects 113 
retinal cells in vitro and in vivo, therefore the age-related CoQ10 decrease might exacerbate 114 
the risk of retinal disease, while supplementation could have a preventative role. Here we 115 
provide an overview of the therapeutic roles of CoQ10 in retinal diseases. 116 
 117 
2. Structure and function of mammalian retina 118 
The neural retinal is a unique structure, consisting of three major cellular layers (outer 119 
nuclear layer, ONL; inner nuclear layer, INL; ganglion cell layer, GCL), separated by 120 
synaptic layers (Figure 2) (17). An outer monolayer, the retinal pigment epithelium (RPE), 121 
underlies the retina and supports photoreceptor function. ONL contains the light-sensitive 122 
photoreceptors, rods and cones. Rods are sensitive to dim light, whereas cones function in 123 
bright light and colour vision. In the central retina of primates, there is a small cone-enriched 124 
area, the ‘macula’, which is functionally specialised for high acuity vision. The central pit of 125 
the macula is the fovea (Figure 2), which contains only cones and provides the sharpest 126 
vision (18). In the retinae of most mammalian species, about 95% of photoreceptors are rods. 127 
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The adult human retina has about 91 million rods and 5 million cones (18). INL is composed 128 
mainly of bipolar cells, although amacrine cells and horizontal cells are also localized in this 129 
layer. Bipolar cells receive synaptic input from photoreceptors and are responsible for 130 
transmitting the signals to ganglion cells directly or indirectly via amacrine cells. Horizontal 131 
cells provide feedback to photoreceptor cells and possibly bipolar cells. Amacrine cells are 132 
inhibitory neurons and interact with retinal ganglion cells via their dendritic arbors (17). The 133 
ganglion cells have long axons, which form the optic nerve, and are responsible for the 134 
transmission of signals from photoreceptors to brain. 135 
      The retina has the highest oxygen consumption rate (per gram tissue) in the body, which 136 
results in the production of a large amount of reactive oxygen and nitrogen species (RONS) 137 
that pose a risk for subsequent cellular damage (19, 20). The retina, particularly the macula, 138 
is also subjected to high light exposure, making photosensitizing molecules, such as retinoids, 139 
vulnerable to light damage. In addition, photoreceptor outer segments are extremely lipid-rich: 140 
about 15% of wet weight content is lipid compared with 1% of wet weight in other types of 141 
cells (21). The photoreceptor outer segments also have a high level of the very-long-chain 142 
polyunsaturated fatty acid (PUFA), which is vulnerable to RONS and are easily oxidisable to 143 
malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE) (20). Cellular systems present 144 
several defence lines against oxidative damage. However, oxidative imbalances occurring as 145 
a result of the ageing process promote oxidative damage that might contribute to the 146 
pathogenesis of retinal diseases.  147 
      Clinical data have demonstrated oxidative stress contributes the pathogenesis of retinal 148 
diseases. Lower total antioxidant capacity has been reported in aqueous humor and sera from 149 
patients with retinitis pigmentosa (RP) (22). In patients with diabetic retinopathy (DR), lipid 150 
peroxidation in serum was significantly increased when compared to that of patients with 151 
diabetes (but with no retinopathy) and there is positive correlation between lipid peroxidation 152 
and disease severity (23, 24). Furthermore, patients with proliferative DR have a markedly 153 
increased serum MDA level compared to that of non-proliferative DR patients (25). Recently 154 
increased oxidative stress level and decreased antioxidant defence have been identified in the 155 
sera from patients with primary open angle glaucoma, pseudoexfoliative glaucoma and 156 
primary angle-closure glaucoma (26, 27). Due to the central role of oxidative stress in the 157 
progression of these diseases, antioxidant therapies may play a role in counteracting retinal 158 
degeneration. Actually antioxidant supplementation in patients with nonproliferative DR 159 
demonstrated retardation of disease progress and maintenance of plasma antioxidant capacity 160 
(28).  161 
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3. Protection of retinal diseases by co-enzyme Q10  162 
3.1 Age related macular degeneration  163 
Age-related macular degeneration (AMD) is the most common cause of blind registration in 164 
the developed world (29). Early AMD is characterized by drusen formation and pigmentary 165 
changes. Late AMD is characterized by geographic atrophy (dry AMD) and / or choroidal 166 
neovascularisation (CNV, wet AMD). Wet AMD presents newly formed immature blood 167 
vessels growing from the choroid through Bruch’s membrane toward the outer retina. Wet 168 
AMD accounts only for about 10-15% of cases, but for 80-90% of resultant blindness. Anti-169 
VEGF (vascular endothelial growth factor) therapies dramatically halt progression of CNV in 170 
the majority of wet AMD patients but there is no effective treatment for AMD patients with 171 
geographic atrophy. An important pathological feature of AMD is the accumulation of both 172 
focal (drusen) and diffuse extracellular (basal) deposits in the macula, between the retinal 173 
pigment epithelium (RPE) and the adjacent Bruch's membrane. These deposits lead to 174 
dysfunction and subsequent death of RPE and associated photoreceptors (30). It is well 175 
recognized that oxidative damage plays an important role in AMD and that antioxidant 176 
supplementation can protect against the condition (31). 177 
       Blasi et al. measured CoQ10 in plasma and platelets of 19 patients with exudative AMD 178 
and 19 age-matched controls (32). They found that most AMD patients had a lower level of 179 
plasma CoQ10 than that of most controls, suggesting a link between CoQ10 level and AMD 180 
(32). Fourteen early AMD patients treated with a mixture including polyunsaturated fatty 181 
acids (1320 mg/day), acetyl-L-carnitine (500 mg/day), CoQ10 (30 mg/day), and vitamin E 182 
(30 mg/day) showed slight improvement in visual functions after three months of treatment; 183 
the improved visual functions remained relatively steady until 24 months. By contrast, the 184 
visual functions of controls treated with vitamin E only (30 mg/day) slowly worsened (33). 185 
The same research group continued to evaluate the treatment efficacy of a combination of 186 
acetyl-L-carnitine, n-3 fatty acids and CoQ10 in early AMD patients for 12 months (34). 106 187 
patients were randomly allocated to two groups: the treated group (51 patients) and the 188 
placebo group (55 patients); four efficacy parameters including visual field mean defect 189 
(VFMD), visual acuity, foveal sensitivity and fundus alteration were measured. The treated 190 
group showed significant improvement in visual function, demonstrating a significant 191 
difference in VFMD, visual acuity and foveal sensitivity when compared to that of the 192 
placebo group. Only 2% of the treated group exhibited clinically related worsening in VFMD 193 




3.2 Glaucoma  196 
Glaucoma is a leading cause of irreversible blindness, affecting more than 70 million people 197 
worldwide (35). It is characterized by the progressive degeneration of retinal ganglion cells. 198 
Intraocular pressure (IOP) is higher in many glaucoma patients and regarded as an important 199 
factor for initiating neuronal damage in these patients. Previous studies demonstrated that 200 
elevated acute and chronic IOP induced oxidative stress in the retina (36-38), resulting in the 201 
oxidative modification of proteins, lipids and DNA (39-41). Primary and secondary hypoxia 202 
(the latter subsequent to elevated IOP) result in oxidative stress and glutamate excitotoxicity, 203 
both of which contribute to ganglion cell dysfunction in glaucoma (42). Histological studies 204 
on glaucomatous eyes from patients and different animal models demonstrated that ganglion 205 
cells were degenerated through apoptosis (43-47). The death of ganglion cells is mainly 206 
caused by oxidative damage via multiple pathogenic mechanisms (42,48). Antioxidants (n-3 207 
PUFAs, α-Lipoic acid and mitochondrially-targeted SKQ1) treatment in glaucoma animal 208 
models showed protection of retinal ganglion dysfunction (49-52). 209 
      CoQ10 has also been used to protect retinal ganglion cell function in the glaucomatous 210 
condition. In vitro studies demonstrated that CoQ10 treatment increased survival of RGC-5 211 
cells (a rat ganglion cell line) from apoptosis when exposed to H2O2, radiation, antimycin (the 212 
complex III inhibitor) or serum starvation (53-55). Administration of CoQ10 in high 213 
intraocular pressure-induced ischemia rat model prevented ganglion cell loss (56). The 214 
protection of ganglion cell death by CoQ10 in ischemic retina was through ameliorating 215 
oxidative stress, blocking apoptosis, preserving mitochondrial function and inhibiting 216 
microglial activation (57). In untreated mouse ischemic retina, the level of superoxide 217 
dismutase 2 (SOD2) and heme oxygenase 1 (HO-1) was significantly increased at 12h after 218 
transient retinal ischemia when compared to non-ischemic control retina; however, CoQ10 219 
treatment preserved SOD2 and HO-1 at levels similar to those of non-ischemic retina. The 220 
level of apoptosis-associated protein Bax was significantly increased in ischemic retina, but 221 
CoQ10 treatment markedly decreased Bax expression. In addition, the expression of glial 222 
fibrillary acidic protein (GFAP, a marker for astroglial cells) and Iba-1 (a marker for 223 
microglial cells) was significantly decreased in CoQ10-treated ischemic retina when 224 
compared to that of non-treated ischemic retina, demonstrating the inhibition of astroglial and 225 
microglial cell activation (57). 226 
      Glutamate excitotoxicity can cause ganglion cell death in glaucoma through the N—227 
methyl-D-aspartate (NMDA) receptor-activated influx of extracellular calcium into cells, 228 
which regulates the activities of cell-death-associated enzymes (42,58). Significantly 229 
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increased retinal extracellular glutamate was detected in pressure-induced ischemic rat model; 230 
intraocular administration of CoQ10 markedly minimized the increase (56). In an 231 
intravitreally NMDA-injection-induced retinal damage mouse model, oral administration of 232 
CoQ10 (10 mg/kg) for 14 days showed that CoQ10 exerted neuroprotective effects by 233 
decreasing ganglion cell death significantly when compared to that of untreated ischemic 234 
retina (53). When CoQ10 was administered as eye drops on mouse cornea, it reached the 235 
choroid/ retina in a dose- and time-dependent manner (55). Moreover, in patients undergoing 236 
vitrectomy CoQ10 administered by eye drops has been shown to penetrate the vitreous body, 237 
where it could function on the retinas (59). In a retinal damage mouse model made by 238 
intravitreal injection with kainite (a glutamate agonist), CoQ10 eye drop treatment 239 
significantly reduced ganglion cell death by inhibiting caspase-dependent apoptosis (55). Lee 240 
et al investigated the neuroprotective effects of CoQ10 in a glaucoma mouse model (DBA/2J) 241 
by feeding the glaucomatous mice with CoQ10 for 6 months (60). The survival of ganglion 242 
cells was markedly increased in the CoQ10 treated mouse retina when compared to that of 243 
mouse fed with a control diet. Similar to the data from retinal ischemic mouse model (57), the 244 
protection of ganglion cell death by CoQ10 also resulted from ameliorating glutamate 245 
excitotoxicity, blocking oxidative stress, maintaining mitochondrial function and inhibiting 246 
astroglial activation (60). Most recently, open-angle glaucoma (OAG) patients treated with 247 
eye drops containing CoQ10 and vitamin E (in addition to a β-blocker monotherapy) for 12 248 
months showed beneficial effects on function of the inner retina (assessed by pattern 249 
electroretinogram) and enhanced visual cortical response (assessed by pattern visual-evoked 250 
potential) (61). 251 
      Astrocytes are the major type of glial cell in the optic nerve head (ONH) and provide 252 
support for axon function (61). During the progression of glaucoma, astrocytes become 253 
activated and are involved in the ONH remodelling associated with the condition (62, 63). 254 
Oxidative stress is known to reactivate ONH astrocytes and is implicated in the pathogenesis 255 
of glaucoma (64, 65). When rat ONH astrocytes were treated with CoQ10 and H2O2, cell 256 
viability and ATP in these cells were both significantly increased, while ROS production was 257 
markedly reduced, when compared to that of cells treated with H2O2 alone. The GFAP, 258 
SOD2 and HO-1 proteins in CoQ10 treated cells were significantly decreased compared to 259 
those of H2O2-treated cells. CoQ10 treatment preserved mitochondrial morphology and 260 
biogenesis by upregulating the expression of the mitofilin and PGC-1α proteins, respectively 261 
(66). These data suggest that CoQ10 can protect ONH astrocytes from oxidative stress mainly 262 
through maintenance of mitochondrial function. 263 
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4. Potential of CoQ10 for the treatment of retinitis pigmentosa and diabetic retinopathy 264 
As oxidative stress also plays a critical role in the pathogenesis of retinitis pigmentosa and 265 
diabetic retinopathy, so CoQ10 has potential for the treatment of both diseases. 266 
4.1 Retinitis pigmentosa 267 
Retinitis pigmentosa (RP, MIM #268000) is a heterogeneous group of conditions involving 268 
progressive degeneration of photoreceptor cells and affects 1/4000 individuals worldwide 269 
(67). The early clinical feature of RP is night blindness, often starting in adolescence, 270 
followed by progressive loss of peripheral vision and late loss of central vision. The 271 
characteristically clinical feature is bone spicule pigment deposits presented in the retinal 272 
fundus (Figure 3). RP may occur alone, as non-syndromic RP, without other clinical features, 273 
or as syndromic RP with different clinical phenotypes.  Most RP cases are presumed to result 274 
from a mutation in one or more genes and may show autosomal dominant, recessive, X-275 
linked, or mitochondrial inheritance, although about one-half of all cases are sporadic. 276 
Mutations in more than 62 genes have been reported to cause non-syndromic RP, including 277 
23 genes associated with autosomal dominant RP, 36 genes associated with recessive RP, and 278 
3 genes associated with X-linked RP (68). 279 
      Death of rod cells in RP occurs through both caspase-dependent and -independent 280 
apoptosis, while death of cone cells occurs primarily through necrosis (69, 70). Oxidative 281 
damage plays a critical role in the death of photoreceptors (69).  Photoreceptors have one of 282 
the highest rates of oxygen consumption in the body and this is particularly high in the 283 
parafoveal region of primates, where rod density is highest (71).  Our previous work showed 284 









) evidenced by significantly reduced retinal complex I 286 
activities (14-29% of wildtype) at a stage when significant photoreceptor loss has not yet 287 
occurred (72). In RP, oxidative damage is also a major contributing factor to cone death 288 
subsequent to the death of rod cells. Further antioxidants have been shown to slow/reduce 289 
cone cell death in different RP animal models (73). Upregulation of antioxidant defences by 290 
over-expression of both superoxide dismutase 2 (SOD2) and catalase in photoreceptor 291 
mitochondria also reduces cone cell death in RP mouse models (74).  292 
      It is desirable to develop new candidates with the potential of reducing reactive oxygen 293 
species (ROS) production and/or upregulating antioxidant defences, which in turn can 294 
potentially slow down retinal degeneration in RP.  295 
4.2 Diabetic retinopathy 296 
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Diabetic retinopathy (DR) refers to the irreversible damage of retinal cells and structures as a 297 
result of chronic diabetes. DR is a progressive disease that is influenced by the duration and 298 
control of diabetes, and its development is believed to occur gradually with different degrees 299 
of disease severity. DR is classified into five stages: no diabetic retinopathy, background 300 
diabetic retinopathy, non-proliferative diabetic retinopathy (NPDR), proliferative diabetic 301 
retinopathy (PDR) and diabetic macular edema (DME) (75, 76). The first stage, no diabetic 302 
retinopathy (Figure 4A), is characterized by normal retinal histology with absence of any 303 
abnormal neovascularization and microvascular abrasions. The second stage, background DR 304 
(Figure 4B), is the earliest stage of DR and is associated with the presence of low grade of 305 
microaneurysm, retinal hemorrhage and exudate. The third stage, non-proliferative diabetic 306 
retinopathy (NPDR), itself includes three phases: mild NPDR (Figure 4C) which involves 307 
microaneurysm; moderate NPDR (Figure 4D) which involves less severe microaneurysm, 308 
intraretinal haemorrhage and microvascular occlusion; and severe NPDR (Figure 4E) which 309 
is characterized by severe and increased rate of intraretinal haemorrhage, microvascular 310 
abnormalities and venous beading. The fourth stage, proliferative diabetic retinopathy (PDR, 311 
Figure 4F), is considered to be a severe phase and is defined by retinal ischemia and 312 
increased rate of abnormal neovascularization in the retina, optic disc and iris with vitreous or 313 
pre-retinal haemorrhage. The fifth stage, diabetic macular edema (DME, Figure 4G), is 314 
associated with relatively increased retinal thickness at the centre of the macula, vascular 315 
permeability and leakage, hard exudate, breakdown of blood-retina barrier (BRB) and retinal 316 
detachment (75, 76). 317 
      Oxidative stress is a common characteristic of DR secondary to hyperglycemia. 318 
Mitochondria are the principal source of energy production. Under normal conditions, 319 
mitochondria provide energy through the electron transport chain (ETC) in which oxygen (O2) 320 
is utilized as the main electron donor and then reduced to ROS to maintain cellular functions; 321 
any increase of ROS level is neutralized by a specialized antioxidant defence system (77). 322 
Mitochondria are the main source of ROS production during diabetes, and studies have 323 
shown that hyperglycemia induces mitochondrial ROS overproduction in response to 324 
increased activation of the polyol pathway, AGEs, PKC pathway, hexosamine biosynthesis, 325 
and poly (ADP-riobose) polymerase. Under physiological conditions excess ROS is 326 
eliminated by specific antioxidant scavengers and balanced by mitochondria maintaining 327 
redox (77). Several antioxidant scavengers such as catalase, superoxide dismutases (SODs) 328 
and glutathione peroxidases (GPXs) have been reported to be involved in oxidative stress 329 
during DR (78-81). Accumulated data from diabetic patients, diabetic animal models and 330 
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high glucose treated cells has revealed that these anti-oxidants may exhibit different gene 331 
expression patterns and activity; the activity of catalase, SODs and GPXs were reported to be 332 
low in diabetic patients, animal models and high glucose treated cells compared to normal 333 
control (78-81). Thus, a therapeutic strategy to directly decrease ROS production and 334 
enhance expression of these anti-oxidants will protect the retina from oxidative stress damage 335 
during DR.      336 
 337 
5. Conclusion 338 
Oxidative stress causes damage to protein, lipid and DNA, which results in retinal cell 339 
dysfunction and death. Mitochondria are the major source of oxidative stress. CoQ10 340 
functions as an electron carrier in the mitochondrial respiratory chain and as an intracellular 341 
antioxidant that offers therapeutic potential for neurodegenerative diseases. Furthermore, due 342 
to its antioxidant properties CoQ10 has demonstrated a protective role in the neuroretina by 343 
counteracting oxidative stress, inhibiting microglia cell activation and maintaining 344 
mitochondrial function. In particular, the role of CoQ10 in modulating mitochondrial 345 
permeability transition pore has been linked to its beneficial effects in preventing the 346 
glutamate-induced cytotoxicity that may contribute to neural degeneration. CoQ10 topical 347 
eye preparation has been shown to be an effective means of delivery to the vitreous cavity 348 
and retina. However, until now only oxidised CoQ10 (ubiquinone) has been tested. The 349 
recent availability of the stable formation of the reduced and active form of CoQ10 350 
(ubiquinol) might represent a ground-breaking innovation in the field. In fact, cellular 351 
metabolism is able to efficiently promote reduction of exogenously provided coenzyme Q10, 352 
while the activity of reducing systems declines with age. 353 
      In conclusion, a significant body of evidence supports a role for CoQ10 in promoting eye 354 
health through inhibiting ROS production and protecting neuroretinal cells from oxidative 355 
damages (Figure 5), although further studies are required to evaluate potential beneficial 356 
effects of ubiquinol eye-drop treatment for patients with retinal diseases, including AMD, 357 
DR, RP and glaucoma, which are major causes of blindness in the world. 358 
 359 
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Figure legends  599 
Figure 1 Coenzyme Q10 is a redox existing in the cellular membranes and consisting of a 600 
quinone ring and 10-isoprenoid-unit tail. There are three states of Coenzyme Q10: fully 601 
oxidized form (ubiquinone), semiquinone (ubisemiquinone) and fully reduced form 602 
(ubiquinol) (A). Coenzyme Q10 is soluble in phospholipid bilayer of the inner mitochondrial 603 
membrane. It is an essential component of the mitochondrial respiratory chain (B). 604 
Ubiquinone can adopt one or two electrons from inner mitochondrial membrane complex I 605 
and II, transforming into semiquinone or ubiquinol by Q10 reductases. Then Q10 transfers 606 
the electrons to complex III. The electron is then passed to complex IV through cytochrome 607 
C. A component of Complex III can convert ubiquinol to ubiquinone to recycle Q10. 608 
Figure 2 The structure of the retina. (A) Cross-sectional image of the heathy retina obtained 609 
by optical coherence tomography (OCT). Scans were taken with the upper panel showing the 610 
64th scan and the lower panel showing the 256th scan. (B) Histological structure of mouse 611 
retina obtained by hematoxylin-eosin staining (left panel) and by immunostaining with 1D4 612 
antibody (labelling the rod outer segments, right panel). GCL, ganglion cell layer; INL, inner 613 
nuclear layer; IS, inner segment; IPL, inner plexiform layer; L, lens; NFL, nerve fiber layer; 614 
ONL, outer nuclear layer; OS, outer segments; RPE, retinal pigment epithelium. 615 
Figure 3 Bone spicule pigment deposits are present in the fundus of retinitis pigmentosa 616 
patient (right side). Fundus of healthy individual is on the left side. Adapted from Raghpathy 617 
et al. (Ref 81)  618 
Figure 4 Clinical classfification of diabetic retinopathy (DR) determined by ophthalmoscopy 619 
(fundoscopy). (A) Heathy retina. (B) Background DR. (C) Mild non-proliferative diabetic 620 
retinopathy (NPDR). (D) Moderate NPDR. (E) Severe NPDR. (F) Proliferative diabetic 621 
retinopathy (PDR). (G) Diabetic macular edema (DME). Adapted from El-Bab et al., 2012 622 
(Ref 82) and Shotliff and Duncan, 2006 (Ref 83).                  623 
Figure 5 Diagram illustrating protection of co-enzyme Q10 (CoQ10) via inhibiting ROS 624 
production.  CoQ10 (ubiquinol) blocks the production of ROS and subsequently attenuates 625 
oxidative damage and inflammation, which reduce death of retinal cells (photoreceptors, 626 
retinal pigment epithelium cells and ganglion cells) and delays the progression of retinal 627 
diseases (age-related macular degeneration, AMD; diabetic retinopathy, DR; retinitis 628 
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